AstraZeneca's New Cancer Regimen Cuts Bladder Cancer Death Risk by 42 Per Cent

2026-10-25 biotech

Brussels, Sunday 25 October 2026
AstraZeneca’s novel drug combination cut the risk of death by 42% in advanced bladder cancer patients, potentially establishing a breakthrough standard of care for those ineligible for standard chemotherapy.

Landmark Clinical Results from the VOLGA Trial

Presented on 24 October 2026 during Presidential Symposium I at the European Society for Medical Oncology (ESMO) Congress in Madrid and simultaneously published in The New England Journal of Medicine, the interim findings from the phase III VOLGA trial demonstrated a 49% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death (hazard ratio 0.51; 95% CI, 0.38–0.67; p < 0.0001) [1][2][3]. The regimen evaluates perioperative Imfinzi (durvalumab) combined with neoadjuvant enfortumab vedotin (EV) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse standard cisplatin-based chemotherapy [1][2]. At a median event-free survival (EFS) follow-up of 22.9 months, the median EFS was not reached in the experimental doublet arm compared to 12.1 months in the comparator cystectomy arm, with 24-month EFS rates standing at 64% versus 45%, respectively [1][3].

Overall Survival and Secondary Clinical Endpoints

The key secondary endpoint of overall survival (OS) revealed a statistically significant 42% reduction in the risk of death (hazard ratio 0.58; 95% CI, 0.40–0.83; p = 0.0027) [1][2][3]. An estimated 78% of patients receiving the Imfinzi and enfortumab vedotin doublet remained alive at two years compared to 69% in the comparator arm [1][2][3]. Pathologic complete response rates showed marked improvements under the perioperative regimen, reaching 45% by local review compared to 10% in the control arm (risk ratio 4.7; 95% CI, 3.1–7.3), and 40% versus 8% under central review [3]. In addition, successful completion of radical cystectomy occurred in 85% of doublet-treated patients versus 78% in the control group [3].

Addressing an Unmet Clinical Need in Bladder Cancer

Bladder cancer ranks as the eighth most common cancer worldwide, accounting for more than 635,000 annual diagnoses, with approximately 25% of cases presenting as muscle-invasive disease [2]. In 2026, an estimated 106,500 patients are projected to receive treatment for MIBC globally [2]. However, up to 50% of these patients cannot receive standard cisplatin chemotherapy prior to radical cystectomy due to renal impairment or other medical comorbidities [2]. Despite undergoing radical cystectomy, disease recurrence historically affects approximately half of all patients [2][5], highlighting the clinical imperative for tolerable perioperative regimens.

Trial Architecture and Arm Comparisons

The randomised, open-label, multi-centre VOLGA trial enrolled 695 patients across 182 centres in 25 countries across Europe, North America, South America, and Asia [1][2]. The study assigned participants 1:1:1 to three treatment groups: the doublet arm (three cycles of neoadjuvant Imfinzi and EV followed by radical cystectomy and nine cycles of adjuvant Imfinzi monotherapy; n = 233), a triplet arm adding the CTLA-4 inhibitor Imjudo (tremelimumab; n = 233), and a radical cystectomy comparator group (n = 229) [1][2][3]. While the tremelimumab triplet arm achieved its primary EFS endpoint with a 39% risk reduction (hazard ratio 0.61; 95% CI, 0.47–0.80; p = 0.0004) and a 60% 24-month EFS rate, its overall survival difference did not achieve statistical significance at this interim analysis (hazard ratio 0.77; 95% CI, 0.54–1.07; p = 0.1230) [3].

Safety Profile and Regulatory Trajectory

Grade 3 and 4 adverse events were recorded in 64% of the doublet combination group compared to 44% in the comparator arm, with overall treatment-related grade 3 or 4 adverse events occurring in 30% of doublet patients and 42% of triplet patients [1][3]. Treatment-related deaths were limited to 1 patient (0.4%) in the doublet arm and 5 patients (2%) in the triplet arm [3]. Following the data cut-off on 2 March 2026, the US Food and Drug Administration granted Priority Review in September 2026 to the perioperative Imfinzi and neoadjuvant enfortumab vedotin regimen for cisplatin-ineligible MIBC [1][2]. This regulatory milestone positions Cambridge-based AstraZeneca [2] to expand Imfinzi’s presence in earlier-stage curative-intent oncology, building upon the more than 470,000 patients treated with the therapy since its initial market approval in May 2017 [2].

Sources & Ecosystem Partners

Clinical trials Oncology therapeutics